These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 24045181)

  • 21. Designed improvement to T-cell immunotherapy by multidimensional single cell profiling.
    Bandey IN; Adolacion JRT; Romain G; Paniagua MM; An X; Saeedi A; Liadi I; You Z; Rajanayake RB; Hwu P; Singh H; Cooper LJ; Varadarajan N
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
    Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
    Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
    Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
    J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-1BB-Enhanced Expansion of CD8
    Harao M; Forget MA; Roszik J; Gao H; Babiera GV; Krishnamurthy S; Chacon JA; Li S; Mittendorf EA; DeSnyder SM; Rockwood KF; Bernatchez C; Ueno NT; Radvanyi LG; Vence L; Haymaker C; Reuben JM
    Cancer Immunol Res; 2017 Jun; 5(6):439-445. PubMed ID: 28473315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
    Teijeira A; Labiano S; Garasa S; Etxeberria I; Santamaría E; Rouzaut A; Enamorado M; Azpilikueta A; Inoges S; Bolaños E; Aznar MA; Sánchez-Paulete AR; Sancho D; Melero I
    Cancer Immunol Res; 2018 Jul; 6(7):798-811. PubMed ID: 29678874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients.
    Ye Q; Song DG; Powell DJ
    Oncoimmunology; 2013 Dec; 2(12):e27184. PubMed ID: 24501691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
    Hu Z; Xia J; Fan W; Wargo J; Yang YG
    Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multifaceted Role of BTLA in the Control of CD8
    Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
    Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.
    Dubrot J; Milheiro F; Alfaro C; Palazón A; Martinez-Forero I; Perez-Gracia JL; Morales-Kastresana A; Romero-Trevejo JL; Ochoa MC; Hervás-Stubbs S; Prieto J; Jure-Kunkel M; Chen L; Melero I
    Cancer Immunol Immunother; 2010 Aug; 59(8):1223-33. PubMed ID: 20336294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expansion of Tumor-Infiltrating CD8
    Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
    Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4-1BB Agonist Focuses CD8
    Sakellariou-Thompson D; Forget MA; Creasy C; Bernard V; Zhao L; Kim YU; Hurd MW; Uraoka N; Parra ER; Kang Y; Bristow CA; Rodriguez-Canales J; Fleming JB; Varadhachary G; Javle M; Overman MJ; Alvarez HA; Heffernan TP; Zhang J; Hwu P; Maitra A; Haymaker C; Bernatchez C
    Clin Cancer Res; 2017 Dec; 23(23):7263-7275. PubMed ID: 28947567
    [No Abstract]   [Full Text] [Related]  

  • 33. Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.
    Seliktar-Ofir S; Merhavi-Shoham E; Itzhaki O; Yunger S; Markel G; Schachter J; Besser MJ
    Front Immunol; 2017; 8():1211. PubMed ID: 29067023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
    Mazzarella T; Cambiaghi V; Rizzo N; Pilla L; Parolini D; Orsenigo E; Colucci A; Modorati G; Doglioni C; Parmiani G; Maccalli C
    Cancer Immunol Immunother; 2012 Aug; 61(8):1169-82. PubMed ID: 22207316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct CD137 costimulation of CD8 T cells promotes retention and innate-like function within nascent atherogenic foci.
    Xu MM; Ménoret A; Nicholas SE; Günther S; Sundberg EJ; Zhou B; Rodriguez A; Murphy PA; Vella AT
    Am J Physiol Heart Circ Physiol; 2019 Jun; 316(6):H1480-H1494. PubMed ID: 30978132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice.
    Forsberg MH; Ciecko AE; Bednar KJ; Itoh A; Kachapati K; Ridgway WM; Chen YG
    J Immunol; 2017 May; 198(10):3857-3868. PubMed ID: 28363905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.
    Tassi E; Bergamini A; Wignall J; Sant'Angelo M; Brunetto E; Balestrieri C; Redegalli M; Potenza A; Abbati D; Manfredi F; Cangi MG; Magliacane G; Scalisi F; Ruggiero E; Maffia MC; Trippitelli F; Rabaiotti E; Cioffi R; Bocciolone L; Candotti G; Candiani M; Taccagni G; Schultes B; Doglioni C; Mangili G; Bonini C
    Front Immunol; 2023; 14():1212444. PubMed ID: 37868997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.
    Kamikawa T; Kimura N; Ishii S; Muraoka M; Kodama T; Taniguchi K; Yoshimoto M; Miura-Okuda M; Uchikawa R; Kato C; Shinozuka J; Akai S; Naoi S; Tomioka N; Nagaya N; Pang CL; Garvita G; Feng S; Shimada M; Kamata-Sakurai M; Aburatani H; Kitazawa T; Igawa T
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39401967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
    Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
    J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
    Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
    Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.